12/26/2025
https://www.npr.org/2025/12/26/nx-s1-5652027/ma*****na-reclassified-trump-executive-order
President Trump's long-anticipated executive order to loosen U.S. restrictions on ma*****na promises to bring immediate relief for cannabis businesses — but only in some respects. And although rescheduling it as a lower-risk drug is touted as opening a new era for cannabis research, experts say it's not as simple as flipping a light switch.
"It's hard to see the big headlines of, 'Ma*****na rescheduled to [Schedule] III; ma*****na research will open,'" says Gillian Schauer, executive director of the nonpartisan Cannabis Regulators Association, which includes agencies from 46 states. "You know, those things are not true as of now."
That's because on its own, Trump's Dec. 18 order isn't enough to rewrite federal drug policy that has stood for more than 50 years.
"The Controlled Substances Act [of 1970] does not grant any president the authority to unilaterally reschedule a drug," Schauer says. Such changes are historically made through either a rulemaking process, or an act of Congress.
Many details will shape how the administration enacts Trump's order, affecting the timeline and scope for easing ma*****na restrictions. But when it does happen, rescheduling won't automatically revoke federal laws targeting ma*****na, and interstate ma*****na commerce would remain illegal, Schauer says.
It's not yet known how other policies might change.
"We don't know what will happen to federal drug testing requirements," Schauer says, until agencies issue guidance.
President Trump set the process in motion to ease federal restrictions on ma*****na. But his order doesn't automatically revoke laws targeting ma*****na, which remains illegal to transport over state lines.